Zomedica Announces Achievement of Therapeutic Development Milestones
Zomedica Corp. Common Shares (ZOM)
US:NYSE Investor Relations:
investors.zomedica.com
Company Research
Source: GlobeNewswire
ANN ARBOR, Mich., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary pharmaceutical and diagnostic company, today announced a development update on the Company's four therapeutic candidates for use in companion animals, namely dogs and cats. “We are pleased that we have achieved the milestones we established earlier this year,” stated Gerald Solensky, Jr., Chief Executive Officer at Zomedica. “2017 was an important year for our pipeline development as we finalized formulations for all four of our lead therapeutic candidates. We look forward to sharing future advancements as development progresses.” ZM-012 and ZM-007: Metronidazole for acute diarrhea in dogs ZM-012 and ZM-007 are complementary oral formulations of metronidazole targeting the treatment of acute diarrhea in dogs. Key development milestones achieved for ZM-012 and ZM-007 in 2017 include: Finalized novel tablet formulation f
Show less
Read more
Impact Snapshot
Event Time:
ZOM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZOM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZOM alerts
High impacting Zomedica Corp. Common Shares news events
Weekly update
A roundup of the hottest topics
ZOM
News
- Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024 [Yahoo! Finance]Yahoo! Finance
- Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024 Accesswire
- Zomedica Corp. (AMEX:ZOM) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity [Yahoo! Finance]Yahoo! Finance
- Zomedica reports Q4 results [Seeking Alpha]Seeking Alpha
ZOM
Earnings
- 8/10/23 - Miss
ZOM
Sec Filings
- 4/4/24 - Form 8-K
- 4/1/24 - Form 10-K
- 3/15/24 - Form 8-K
- ZOM's page on the SEC website